Breaking News
Sort by:
Top Post
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ ®, an Adjuvanted Plant-based COVID-19 Vaccine
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health […]
Evaluating the Effects of ACE2-Mediated Covid-19 Infection
Covid-19 has impacted virtually everyone‘s lives, whether through personal experience of infection or the impacts […]
NHS Vaccination Lead Comments On Boosters Preventing An Estimated 105,000 Hospitalisations
Commenting on analysis published by the UKHSA today estimating that over 105,000 hospitalisations in people […]
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) […]
England to Return to Plan A Following the Success of the Booster Programme
The government has today announced that England will fully return to Plan A on Thursday […]
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing […]
NHS Strikes New Covid Surge Deal With Independent Sector
Local hospitals will be able to quickly activate surge capacity in the independent sector as […]
Avacta Provides Update on AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
Leiden Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against […]
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) announced that the U.S. government has committed to purchasing an additional 10 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more